{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-022587","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.191229+00:00","generated_at":"2026-06-24T00:20:22.848753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"VYNE Therapeutics Q2 2022 net loss $8.5M, improved from $19.9M YoY","bullets":["GAAP loss from continuing operations $8.2M in Q2 2022 vs $10.7M in Q2 2021.","Adjusted net loss (non-GAAP) $7.3M in Q2 2022 vs $18.0M in prior year.","Six-month adjusted net loss $1.8M vs $36.1M in H1 2021, driven by discontinued operations.","CEO highlights BET inhibitor platform potential for immuno-inflammatory diseases.","No revenue reported; company remains in development stage."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-022587","json":"https://secwatch.observer/filing/0001628280-22-022587.json","markdown":"https://secwatch.observer/filing/0001628280-22-022587.md","text":"https://secwatch.observer/filing/0001628280-22-022587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828022022587/0001628280-22-022587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828022022587/mnlo-20220812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:20:22.848753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}